Inactive Instrument

Oncorus, Inc.

Equities

ONCR

US68236R1032

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Fed Seen Holding Rates, Powell Comments Key DJ
North American Morning Briefing : Inflation -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Nvidia Results -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Traders Absorb -2- DJ
Oncorus, Inc. Announces Executive Changes CI
Oncorus, Inc. Announces Changes to Its Board CI
Oncorus, Inc. Announces Executive Changes CI
Oncorus, Inc. Announces Board Changes CI
Oncorus, Inc. Announces Resignation of Douglas M. Fambrough III from its Board of Directors as Well as Compensation Committee, Effective July 20, 2023 CI
Oncorus, Inc. Enters into Lease Termination Agreement with IQHQ-4 Corporate, LLC CI
Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index CI
Oncorus, Inc.(OTCPK:ONCR) dropped from NASDAQ Composite Index CI
Oncorus Announces Management Changes CI
Oncorus Appoints Brian Shea as Interim Chief Executive Officer CI
Debt Limit Deal Approval, Jobs Data in Focus Amid Higher Exchange-Traded Funds, Equity Futures Pre-Bell Friday MT
North American Morning Briefing : Stock Futures Rise as Jobs Report Swings Into Focus DJ
Oncorus to Lay Off Almost Entire Workforce -- Shares Slump After-Hours MT
Stocks to Watch : Lululemon, Lava Therapeutics, Tilly's, Oncorus DJ
Oncorus, Inc. Announces Workforce Reduction Plan CI
Theodore Ashburn, Chief Executive Officer Departs from the Oncorus, Inc, Effective to Be No Later Than June 30, 2023 CI
Oncorus, Inc. Announces Management Changes, Effective to Be No Later Than June 30, 2023 CI
Oncorus, Inc. Contemplates Bankruptcy CI
Oncorus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart Oncorus, Inc.
More charts
Oncorus, Inc. is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The Company's two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The Company intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The Company is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The Company designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.
More about the company
  1. Stock
  2. Equities
  3. Stock Oncorus, Inc. - OTC Markets
  4. News Oncorus, Inc.
  5. Oncorus Says Initial Data on ONCR-177 Show Clinical Benefit for Three Out of Eight Patients With Solid Tumors; Shares Sink